Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Adenocarcinoma of unknown primary" to "Carcinoma of unknown primary") Tags: mobile edit mobile web edit |
|||
| Line 10: | Line 10: | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| − | *[[ | + | *[[Carcinoma of unknown primary]] |
*[[Adrenocortical carcinoma]] | *[[Adrenocortical carcinoma]] | ||
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
| Line 137: | Line 137: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| − | [[Category: | + | [[Category:Carcinoma of unknown primary medications]] |
[[Category:Adrenocortical carcinoma medications]] | [[Category:Adrenocortical carcinoma medications]] | ||
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
Revision as of 00:55, 22 May 2021
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Carcinoma of unknown primary
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Cholangiocarcinoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Follicular lymphoma
- Hemophagocytic lymphohistiocytosis
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Low-grade glioma
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- NK- and T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
Patient drug information
- Etoposide (Vepesid) package insert[1]
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/10/1983: Initial FDA approval for refractory testicular tumors
- Unclear date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment
Also known as
- Code names: VP-16, VP-TEC, VP 16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepesid | Vepeside | Vepsid | Vepside | ||||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cholangiocarcinoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Hemophagocytic lymphohistiocytosis medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- NK- and T-cell lymphoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Kaposi sarcoma medications
- FDA approved in 1983
- WHO Essential Cancer Medicine